article

1. Psychoneuroimmunology in multiple myeloma and autologous hematopoietic stem cell transplant: Opportunities for research among patients and caregivers..  Brain, behavior, and immunity.  507-519. 2024
2. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review..  Journal of geriatric oncology.  15:-. 2024
3. Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma..  Haematologica.  108:3477-3479. 2023
4. Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma..  Blood cancer journal.  13:-. 2023
5. Associations of frailty with symptoms, and HRQOL in older cancer survivors after cancer treatments: a systematic review and meta-analyses..  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.  33:583-598. 2023
6. Understanding the health effects of caregiving stress: New directions in molecular aging..  Ageing research reviews.  -. 2023
7. Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer..  The oncologist.  28:e625-e632. 2023
8. Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma..  Frontiers in oncology.  -. 2023
9. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  41:4293-4312. 2023
10. Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia..  Journal of geriatric oncology.  14:-. 2023
11. The Transplant Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Patients..  Transplantation and cellular therapy.  29:632.e1-632.e10. 2023
12. A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma..  Cancer.  129:2023-2034. 2023
13. The association between religiosity, mental health, and cognitive functioning among older adults with hematologic malignancies..  Journal of geriatric oncology.  14:-. 2023
14. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review..  Blood cancer journal.  13:-. 2023
15. Infrastructure to Support Accrual of Older Adults to National Cancer Institute Clinical Trials..  Journal of the National Cancer Institute. Monographs.  2022:151-158. 2022
16. Outcomes After Salvage Autologous Hematopoietic Cell Transplant for Patients With Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience..  Clinical lymphoma, myeloma & leukemia.  23:e182-e189. 2022
17. Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review..  PloS one.  17:-. 2022
18. Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma..  Clinical lymphoma, myeloma & leukemia.  23:e85-e96. 2022
19. Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma..  Journal of clinical medicine.  11. 2022
20. Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma..  Leukemia.  36:2917-2921. 2022
21. Racial differences as predictors of outcomes in young patients with multiple myeloma..  Blood cancer journal.  12:-. 2022
22. Characterization of older adults with cancer seeking acute emergency department care: A prospective observational study..  Journal of geriatric oncology.  13:943-951. 2022
23. Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience..  Cancers.  14. 2022
24. Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias..  Frontiers in oncology.  -. 2022
25. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review..  Transplantation and cellular therapy.  28:294-302. 2022
26. Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant..  Frontiers in oncology.  -. 2022
27. Multidisciplinary Approach to Older Adults with Hematologic Malignancies-a Paradigm Shift..  Current hematologic malignancy reports.  17:31-38. 2022
28. Treatment of older adult or frail patients with multiple myeloma..  Hematology. American Society of Hematology. Education Program.  2021:46-54. 2021
29. Integration of a Geriatric Assessment With Intervention in the Care of Older Adults With Hematologic Malignancies..  Frontiers in oncology.  -. 2021
30. NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021..  Journal of the National Comprehensive Cancer Network : JNCCN.  19:1006-1019. 2021
31. Feasibility of implementing an exercise intervention in older adults with hematologic malignancy..  Journal of geriatric oncology.  13:234-240. 2021
32. Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation..  Journal of clinical medicine.  10. 2021
33. Advances in Management for Older Adults With Hematologic Malignancies..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  39:2102-2114. 2021
34. The Cancer and Aging Research Group (CARG) infrastructure: The clinical implementation core..  Journal of geriatric oncology.  12:1164-1165. 2021
35. Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults..  Transplantation and cellular therapy.  27:617.e1-617.e7. 2021
36. Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic Malignancy..  Journal of the National Comprehensive Cancer Network : JNCCN.  19:1027-1036. 2021
37. Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer..  Journal of geriatric oncology.  12:813-819. 2021
38. Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients..  Frontiers in oncology.  -. 2021
39. Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation..  Cancers.  13. 2021
40. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival..  Cancer medicine.  10:965-973. 2020
41. Discharge Disposition Following Hematopoietic Cell Transplantation: Predicting the Need for Rehabilitation and Association with Survival..  Transplantation and cellular therapy.  27:337.e1-337.e7. 2020
42. Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper..  Journal of geriatric oncology.  12:499-507. 2020
43. AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes..  Journal of clinical medicine.  9. 2020
44. Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020..  Journal of clinical medicine.  9. 2020
45. Prevalence of lifestyle behaviors and associations with health-related quality of life among older female cancer survivors..  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.  29:3049-3059. 2020
46. Let's get it on: Addressing sex and intimacy in older cancer survivors..  Journal of geriatric oncology.  12:312-315. 2020
47. Association of Prediagnostic Frailty, Change in Frailty Status, and Mortality After Cancer Diagnosis in the Women's Health Initiative..  JAMA network open.  3:-. 2020
48. Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies..  Journal of geriatric oncology.  12:235-238. 2020
49. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults..  Blood advances.  4:3528-3549. 2020
50. Implementing a multidisciplinary approach for older adults with Cancer: geriatric oncology in practice..  BMC geriatrics.  20:-. 2020
51. Multidisciplinary telemedicine and the importance of being seen..  Journal of geriatric oncology.  11:1349-1351. 2020
52. Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma..  Journal of geriatric oncology.  11:764-768. 2020
53. Fluoroquinolone Prophylaxis in Autologous Stem Cell Transplantation: Worthy of a Second Look..  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.  26:e198-e201. 2020
54. Heavy Lifting: Nomenclature and Novel Therapy for Gamma Heavy Chain Disease and Other Heavy Chain Disorders..  Clinical lymphoma, myeloma & leukemia.  20:493-498. 2020
55. Newly Diagnosed Myeloma in 2020..  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.  1-15. 2020
56. Simplified frailty assessment tools: are we really capturing frailty or something else?.  Leukemia.  34:1967-1969. 2020
57. Use of geriatric assessment in hematopoietic cell transplant..  Journal of geriatric oncology.  11:225-236. 2019
58. Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up..  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.  26:44-49. 2019
59. T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma..  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.  26:7-15. 2019
60. A story of connection: A tribute to Arti Hurria, MD..  Journal of geriatric oncology.  11:164-165. 2019
61. Approach to the Older Adult With Multiple Myeloma..  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.  500-518. 2019
62. BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas..  Bone marrow transplantation.  54:1553-1561. 2019
63. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma..  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.  25:1107-1115. 2019
64. Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT)..  Archives of hematology and blood diseases.  2:12-18. 2019
65. Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant..  CPT: pharmacometrics & systems pharmacology.  7:748-758. 2018
66. Most multiple myeloma patients have low testosterone..  Leukemia & lymphoma.  60:836-838. 2018
67. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant..  Journal of geriatric oncology.  10:479-485. 2018
68. Frailty in Hematologic Malignancy..  Current hematologic malignancy reports.  13:143-154. 2018
69. A call to action in hematologic disorders: A report from the ASH scientific workshop on hematology and aging..  Journal of geriatric oncology.  9:287-290. 2018
70. Incidence and survival of hematological cancers among adults ages ≥75 years..  Cancer medicine.  7:3425-3433. 2018
71. Ninety-minute daratumumab infusion is safe in multiple myeloma..  Leukemia.  32:2495-2518. 2018
72. Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients..  Bone marrow transplantation.  53:1418-1427. 2018
73. Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial..  Clinical pharmacology and therapeutics.  102:511-519. 2017
74. Reprint of: Aging: Treating the Older Patient..  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.  23:S10-S17. 2017
75. Aging: Treating the Older Patient..  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.  23:193-200. 2016
76. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia..  American journal of hematology.  92:42-49. 2016
77. Survivorship care for older adults with cancer: U13 conference report..  Journal of geriatric oncology.  7:305-12. 2016
78. Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers..  Journal of proteomics.  89-98. 2016
79. Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma..  Bone marrow transplantation.  50:1379-81. 2015
80. The devil is in the details: confidentiality challenges in the age of genetics..  HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues.  27:79-86. 2015
81. Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL Microenvironment..  Journal of leukemia (Los Angeles, Calif.).  2. 2014
82. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma..  Clinical cancer research : an official journal of the American Association for Cancer Research.  20:5946-55. 2014
83. Multiple myeloma in the older adult: better prospects, more challenges..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  32:2531-40. 2014
84. Vancomycin-resistant enterococci infection: not just for the transplanted..  Leukemia & lymphoma.  55:1320-5. 2013
85. Preventing acute leukemia relapse after allogeneic transplants: how to move forward?.  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.  19:2-3. 2013
86. Refining hematopoietic cell transplant: a concise review..  Cytometry. Part B, Clinical cytometry.  82:266-7. 2012
87. Salvage chemotherapy and autologous hematopoietic cell transplant in primary refractory diffuse large B-cell lymphoma: progress or better patient selection?.  Leukemia & lymphoma.  53:756-7. 2012